Réaliser une revue récente comportant les particularités épidémiologiques, histologiques des patients nouvellement diagnostiqués d’un cancer de sein à Casablanca durant l’année 2018. Nous avons colligé 668 cas pendant l’année 2018, l’âge moyen était 51,6 ans, le sexe féminin était le plus représenté avec 662 cas (99,1%) et les hommes avec 6 cas (0,9%), soit un sexe ratio (H/F) de 0,009. L’âge moyen de la ménopause était 49,8 ans et l’âge moyen de la ménarche était 13,5 ans, 31,7% avait un antécédent de cancer (le sein 14,1%, l’estomac 9% et le foie 7%). Le délai moyen de consultation était 10 mois, la pathologie la plus représentée était la pathologie thyroïdienne. Selon la localisation, le sein gauche était atteint dans 50,2% et le sein droit dans 44,7% et une localisation bilatérale 1,3%, le siège le plus fréquent était le quadrant supérieur externe avec 28,7%, les stades T1 et T2 représentaient 73,6% et les stades T3 et T4 représentaient 26,4%, les tumeurs épithéliales infiltrantes carcinome canalaire infiltrant (CCI) étaient les plus fréquentes (73,2%). La présence des emboles vasculaires et lymphatiques a été notée chez 42,2%, les ganglions axillaires étaient atteints chez 71,1% des patients. Le grade histopronostique de Scarff Bloom et Richardson (SBR) avait révélé une prédominance du grade II dans 55,9% des cas. Le Luminal B continue à constituer le phénotype le plus fréquent (46%) suivi du Triple Negatif (15,3%) et du Luminal A (14,2%) et enfin le HER2 (7,4%). Le pronostic immédiat demeure inquiétant du fait du retard de diagnostic. Il nous paraît urgent de mettre en place une politique sanitaire d’information et d’éducation.

Male breast cancer is a rare disease accounting for less than 1% of all breast cancer diagnoses worldwide to our knowledge. The aim of this retrospective study is to analyse the epidemiologic, clinical, therapeutic and evolutive profiles of this disease and to compare some cancer aspects between male and female in 25 cases collected at Mohamed VI Oncology Center at the University Hospital of Casablanca between 2012 and 2018. Of all breast cancers, men with breast cancer make up a minority. Male compared to female breast cancers occurred later in life with higher stage and more estrogen receptor-positive tumors. The median age was 67.7 years. The average diagnosis delay was 15.7 month. Cancer was discovered through self examination in 76.1% of cases. The mean diameter was 3.5 cm and range from 1-6 cm. According to the tumor-node-metastasis (TNM) classification, tumors were classified as T1-T2 (40%) and T3-T4 (60%). Infiltrating ductal carcinoma was the most frequent (92%) and 1 case of lobular carcinoma. Axillary nodal involvement was present in 82.4% of cases. Hormonal receptors were positive in 83% of cases. 86.6% of our cases present metastasis. Bone was the most representative site. Surgery was usually mastectomy with axillary clearance. It was possible to follow 21 of the patients. The median of follow-up was 12 months. The evolution has been characterized by local recurrence in 6 cases. There was 9 cases of death. Death was usually due to comorbid disease and to the advanced age. The 5 years overall survival rates were 57%.

Nowadays, cancer is a huge public health challenge that needs for more advanced researches. Quality of life of patients with breast cancer is an important outcome. Data analyses are usually referred to female breast cancer studies and limited informations are available about male breast cancer. Our study is the first in our country to assess quality of life (QoL) in male patients affected by breast cancer. The purpose of this study is to investigate HRqol (health related quality of life) in male patients with breast cancer and clinico-pathological features at the university hospital of Casablanca, Morocco over a period of 6 years. This study involved 21 male subjects from 2012 to 2018. Required information were collected from the medical records of patients in the oncological center. We included demographic, clinical and pathological characteristics. HRqol was investigated using the European Organization for Research and Treatment of Cancer 30-Item QoL Questionnaire (EORTC QLQ-C30), version 3.0. Mean age of patients at enrollment was 67.3 years (SD=15.6, range=36-87 years), the average consultation delay was 17,7 months, the most common histologic finding was infiltrating ductal adenocarcinoma (20 patients, 95.3%). Progesterone and estrogen receptors were positives in 90.4% (19 patients) of cases, the most representative stage was stage III, the most common molecular phenotype was Luminal B (16 patients, 76.2%), modified radical mastectomy was the main surgical procedure. Adjuvant therapy was based on chemotherapy (100%), radiotherapy (76.2%), hormone therapy (90.5%). Ten patients (47.6%) had metastasis. A moderate overall quality of life was reported, with a mean of 50±21.73. The results showed a mean physical function score (54.60±27.85), positive emotional functioning (56.34±31.94) and good social functioning (75.39±17.96). In brief, regarding QOL in this population, it appears to be better than expected andQOL generally improves after treatment. As for prevention, public education should be oriented toward men at higher risk in order to reduce the time between onset of symptoms and consultation.